Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOUNTAINEER: Tucatinib + Trastuzumab in HER2+ mCRC
NCT03043313Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Jun 2017
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of tucatinib in metastatic colorectal cancer (mCRC), sponsored by Seagen Inc.. Started Jun 2017; status: completed.
02
Drugs
tucatinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03043313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043313.